---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-030505"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:30:29.333219+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51

## Summary
- FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.
- PGN-EDO51 targets DMD patients whose mutations are amenable to exon 51 skipping approach.
- Ongoing CONNECT1 Phase 2 trial; CONNECT2 Phase 2 enrollment expected later in 2024.
- Orphan designation offers 7-year U.S. exclusivity plus tax credits and fee benefits upon approval.
- Rare pediatric disease designation may yield a priority review voucher for a future product.

## SEC filing metadata
- accession: 0000950170-24-030505
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/0000950170-24-030505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/pepg-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-030505
- JSON: https://secwatch.observer/filing/0000950170-24-030505.json
- Plain text: https://secwatch.observer/filing/0000950170-24-030505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.